Novo chief on approval of prize asset: Probably the biggest achievement

The approval of Novo Nordisk’s GLP-1 analogue Ozempic is probably “the biggest” achievement for chief science officer (CSO) Mads Krogsgaard Thomsen during his 26 years in the Danish diabetes group. He is happy that the company now possesses the two best products of the drug class.

Photo: /ritzau/Peter Hove Olesen

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Omstridt parallelimportør går konkurs

Parallelimportøren Europharma, der to gange i 2017 blev suspenderet af Lægemiddelstyrelsen, er gået konkurs. Selskabet har erkendt, at et varelager for 50 mio. kr. er usælgeligt.

Related articles